Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, had an estimated annual sale of $122 million in the U.S
| Photo Credit: DANISH SIDDIQUI
Generic drugmaker Lupin has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the U.S.
Bioequivalent of Eli Lilly and Company’s Glucagon for Injection, 1 mg/vial, the product is indicated for treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. It is also used as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, had an estimated annual sale of $122 million in the U.S., Lupin said in a release on Monday citing IQVIA MAT June 2025 numbers. It had received U.S. FDA approval for this and another generic diabetes drug in July.
Lupin shares closed 1.53% at ₹1,946.15 each on the BSE.
Published – August 11, 2025 09:38 pm IST
